Mills Oakley

In the ACCC’s price-fixing case, infrastructure services company Ventia has joined with Spotless in arguing the companies were not in competition, and says it was the Department of Defence that arranged for the providers to talk.

Lendlease has told a court that documents relied on by an ex-Greenwoods and Herbert Smith Freehills partner in his case contain privileged legal advice and without prejudice communications with the Australian Tax Office.

A court has dismissed a client’s attempt to join Kheir Lawyers to an action against Shine Lawyers, after the application -- repleaded for a fourth time -- remained “indefensible".

An injured construction worker has failed in his plea to the High Court to weigh in on his case, which alleged a principal contractor owed a duty of care to him as a sub-contractor's employee.

An appeals court has rejected Keybridge CEO Nick Bolton's challenge to a ruling that found that he and two other directors were validly removed at a board meeting, finding in favour of shareholder WAM Active. 

The owners corporation of a 98-unit Parklea development by defunct builder Dyldam Developments has failed in its attempt to claim insurance for building defects in a property completed 17 years ago, with a court finding that time was up. 

Downer EDI subsidiary Spotless has rejected allegations it engaged in price-fixing with Ventia on defence contracts, saying the facilities services companies were not in competition with each other.

Kent Projects, the engineering firm behind the world-first Kwinana energy transformation hub in WA, is not giving up its fight against fraud claims in a case by the CFMEU.

Property developer Mirvac has successfully challenged the land tax valuation of a North Sydney office block, securing a $6.25 million reduction following a conciliation conference with the Valuer General of NSW.

A judge has declined to make orders blocking a general meeting of the members of Cryptai, a company with a significant shareholding in Sam Altman-backed Ai company Rain Neuromorphics, in order to consider a share sale.